Calliditas Therapeutics AB Share Price

Equities

CALTX

SE0010441584

Pharmaceuticals

Market Closed - Nasdaq Stockholm 17:00:00 19/07/2024 BST 5-day change 1st Jan Change
206.4 SEK 0.00% Intraday chart for Calliditas Therapeutics AB +0.29% +62.39%

Financials

Sales 2024 * 1.88B 176M 13.61B Sales 2025 * 3.21B 301M 23.3B Capitalization 11.15B 1.05B 80.92B
Net income 2024 * -62M -5.81M -450M Net income 2025 * 1.13B 106M 8.18B EV / Sales 2024 * 6.03 x
Net Debt 2024 * 154M 14.45M 1.12B Net cash position 2025 * 1.11B 104M 8.09B EV / Sales 2025 * 3.13 x
P/E ratio 2024 *
73.8 x
P/E ratio 2025 *
10.3 x
Employees 219
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.35%
More Fundamentals * Estimated data
Dynamic Chart

Latest transcript on Calliditas Therapeutics AB

1 week+0.29%
Current month+0.39%
1 month+0.78%
3 months+105.37%
6 months+69.32%
Current year+62.39%
More quotes
1 week
203.80
Extreme 203.8
206.60
1 month
203.80
Extreme 203.8
208.00
Current year
93.65
Extreme 93.65
208.80
1 year
80.80
Extreme 80.8
208.80
3 years
58.70
Extreme 58.7
208.80
5 years
50.40
Extreme 50.4
208.80
10 years
39.14
Extreme 39.135
208.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 17/05/17
Director of Finance/CFO 47 31/07/17
Chief Tech/Sci/R&D Officer 60 23/07/20
Members of the board TitleAgeSince
Director/Board Member 73 29/05/23
Director/Board Member 57 31/12/21
Chairman 65 07/05/19
More insiders
Date Price Change Volume
19/07/24 206.4 0.00% 146,553
18/07/24 206.4 0.00% 177,180
17/07/24 206.4 +0.39% 129,922
16/07/24 205.6 -0.10% 309,396
15/07/24 205.8 0.00% 97,028

Delayed Quote Nasdaq Stockholm, July 19, 2024 at 05:00 pm

More quotes
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
206.4 SEK
Average target price
221.2 SEK
Spread / Average Target
+7.19%
Consensus